テネシーにおける血液がんの臨床試験
テネシー内の拠点で、血液がんに関する20件の研究が参加者を募集しています。
テネシー内の都市
公式研究テキスト（英語）
Long-term Safety and Efficacy Extension Study for Participants With Advanced Tumors Who Are Currently on Treatment or in Follow-up in a Pembrolizumab (MK-3475) Study (MK-3475-587/KEYNOTE-587)
- Vanderbilt Health One Hundred Oaks Diagnostic ( Site 0060), Nashville
- Vanderbilt University Medical Center-Vanderbilt-Ingram Cancer Center ( Site 0015), Nashville
被験者募集中第3相
18歳以上 · 全性別 · 2026/10/02更新 · NCT03486873A Study of JNJ-95804306 for Relapsed or Refractory Hematological Malignancies
- Sarah Cannon Cancer Institute, Nashville
被験者募集中第1相
18歳以上 · 全性別 · 2026/09/25更新 · NCT07572006Pivotal Open-label Phase 3 Clinical Study of QTX-2101 in Adult Patients With Acute Promyelocytic Leukemia
- Quetzal Site 12, Nashville
被験者募集中第3相
18歳〜71歳 · 全性別 · 2026/09/23更新 · NCT07504458A Study to Evaluate INCA036873 in Participants With Advanced Solid Tumors and Hematological Malignancies
- Scri Oncology Partners, Nashville
- Vanderbilt Medical Center, Nashville
被験者募集中第1相
18歳以上 · 全性別 · 2026/09/15更新 · NCT07195916CD45RA-depleted CD19-CAR T Cell Consolidation After TCRαβ+/CD19 B Cell-depleted Haploidentical Hematopoietic Cell Transplantation for Relapsed/Refractory CD19+ ALL and Lymphoma
- St. Jude Children's Research Hospital, Memphis
被験者募集中第1相
21歳以下 · 全性別 · 2026/08/28更新 · NCT07257419Studies to Assess Ziftomenib in Combination With Ven+Aza or 7+3 in Patients With Untreated NPM1-m or KMT2A-r AML
- Baptist Clinical Research Institute, Memphis
- Tennessee Oncology, Nashville
- TriStar Centennial Medical Center, Nashville
被験者募集中第3相
18歳以上 · 全性別 · 2026/08/20更新 · NCT07007312Safety and Tolerability of Ziftomenib Combinations in Patients With Relapsed/Refractory Acute Myeloid Leukemia
- Vanderbilt University Medical Center, Nashville
被験者募集中第1相
18歳以上 · 全性別 · 2026/08/20更新 · NCT06001788A Phase 1 Study of IM-1021 in Participants With Advanced Cancer
- Sarah Cannon Research Institute - Oncology Partners, Nashville
被験者募集中第1相
18歳以上 · 全性別 · 2026/08/10更新 · NCT06823167Trial of Orca-T Following Reduced Intensity or Nonmyeloablative Conditioning in Patients With Acute Myeloid Leukemia or Myelodysplastic Syndrome
- Vanderbilt University, Ingram Cancer Center, Nashville
被験者募集中第2相
18歳以上 · 全性別 · 2026/07/07更新 · NCT07216443A Multicenter Access and Distribution Protocol for Unlicensed Cryopreserved Cord Blood Units (CBUs)
- St. Jude Childrens Research Hospital, Memphis
- Vanderbilt University, Nashville
被験者募集中観察研究
全年齢 · 全性別 · 2026/07/06更新 · NCT01351545Prospective Evaluation Of Delayed Effects Of Pediatric Car T Cell Therapy
- St. Jude Children's Research Hospital, Memphis
被験者募集中観察研究
30歳以下 · 全性別 · 2026/06/18更新 · NCT06579469Long-term Follow-up After Adoptive Transfer of Genetically Modified Cell Products
- St. Jude Children's Research Hospital, Memphis
被験者募集中観察研究
全年齢 · 全性別 · 2026/06/17更新 · NCT05713214Response to Influenza Vaccination in Pediatric Oncology Patients
- St. Jude Children's Research Hospital, Memphis
被験者募集中観察研究
18歳以下 · 全性別 · 2026/06/12更新 · NCT05384288TCRαβ-depleted Progenitor Cell Graft With Early Memory T-cell DLI, Plus Selected Use of Blinatumomab, in naïve T-cell Depleted Haploidentical Donor Hematopoietic Cell Transplantation for Hematologic Malignancies
- St. Jude Children's Research Hospital, Memphis
被験者募集中第1相健康なボランティア歓迎
21歳以下 · 全性別 · 2026/06/02更新 · NCT07052370A Study of the Drug Letermovir as Prevention of Cytomegalovirus Infection After Stem Cell Transplant in Pediatric Patients
- The Children's Hospital at TriStar Centennial, Nashville
- Vanderbilt University/Ingram Cancer Center, Nashville
被験者募集中第3相
2歳〜18歳 · 全性別 · 2026/05/05更新 · NCT05711667A Study to Investigate the Safety and Tolerability of Ziftomenib in Combination With Venetoclax/Azacitidine, Venetoclax, 7+3, or 7+3+Quizartinib in Patients With AML
- TriStar Bone Marrow Transplant, Nashville
被験者募集中第1相
18歳以上 · 全性別 · 2026/03/13更新 · NCT05735184CAR T-cell Therapy Directed to CD70 for Pediatric Patients With Hematological Malignancies
- St. Jude Children's Research Hospital, Memphis
被験者募集中第1相
21歳以下 · 全性別 · 2026/01/23更新 · NCT06326463IDP-023 as a Single Agent and in Combination With Antibody Therapies in Patients With Advanced Hematologic Cancers
- SCRI Oncology Partners, Nashville
被験者募集中第1/2相
18歳以上 · 全性別 · 2025/06/03更新 · NCT06119685Tagraxofusp in Pediatric Patients With Relapsed or Refractory CD123 Expressing Hematologic Malignancies
- St. Jude Children's Research Hospital, Memphis
被験者募集中第1相
1歳〜21歳 · 全性別 · 2024/12/06更新 · NCT05476770Study of VIP943 in Subjects With Advanced CD123+ Hematologic Malignancies
- TriStar Bone Marrow Transplant, Nashville
被験者募集中第1相
18歳以上 · 全性別 · 2024/11/15更新 · NCT06034275ClinicalTrials.govより、2026/10/05時点のデータを取得。各研究には独自の参加資格があり、参加可否は研究チームが決定します。